KDM6A and hepatocellular carcinoma: Preclinical research has demonstrated that combining Donafenib with GSK-J4, a histone demethylase KDM6A/B inhibitor, produces a synergistic lethality effect in HCC across various models, including cellular systems, organoids, and subcutaneous xenografts derived from patients and mutant mouse models (Zheng C. et al., 2023).